• CSCO 2024丨Advancing NSCLC Treatment: Dr. Changli Wang on the Promise of Perioperative Immunotherapy

    The 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. Multiple forums on lung cancer were held during the conference, summarizing the latest advances in…

  • ESMO 2024 Highlights: Dr. Ben J. Solomon on Alectinib’s Biomarker Analysis

    The 2024 European Society for Medical Oncology (ESMO) Congress took place from September 13 to 17 in Barcelona, Spain, where significant progress in lung cancer research was unveiled. Dr. Ben J. Solomon, from the Peter MacCallum Cancer Centre in Melbourne, Australia, shared the results of the biomarker analysis from the ALINA study. In an exclusive…

  • ESMO 2024 Update: Dr. Xiao Chen on Ilourac’s Sustained PFS Benefits

    Ilourac (WX-0593) is a next-generation, potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), showing both systemic and central nervous system (CNS) efficacy in patients with ALK-positive non-small cell lung cancer (NSCLC). At the 2024 ESMO Congress, updated data from the INSPIRE study were presented in a poster session, showing continued progression-free survival (PFS) improvement…

  • ESMO 2024 Insights: Dr. Jie Chen on CABINET and CVM-005 Trials in NETs

    The 2024 European Society for Medical Oncology (ESMO) Annual Meeting has successfully concluded. Several studies presented during the neuroendocrine tumor (NET) oral sessions have offered new treatment strategies and molecular profiling for advanced unresectable NETs. Notably, the Phase III CABINET study on cabozantinib achieved its primary endpoint of progression-free survival (PFS), and the multi-center single-arm…

  • WCLC 2024 Update: Dr. Baohui Han Discusses the DUBLIN-3 and DURABLE Trials

    The 2024 World Conference on Lung Cancer (WCLC) was held in San Diego from September 7-10, featuring major studies from Chinese scholars. Oncology Frontier had the opportunity to interview Dr. Baohui Han from Shanghai Chest Hospital, inviting her to interpret the results of the DUBLIN-3 and DURABLE clinical trials.

  • Hepatology | Association Between Metabolic-Associated Fatty Liver Disease and Subclinical Hypothyroidism in Adolescents

    Subclinical hypothyroidism, previously referred to as mild thyroid dysfunction or impaired thyroid reserve, is increasingly detected due to advancements in thyroid function testing. Research has shown that subclinical hypothyroidism is…

  • Non-KPC Characteristics of Novel BL/BLI Compounds in Pseudomonas aeruginosa

    Resistance Mechanisms of Pseudomonas aeruginosa Compared to Enterobacterales, the resistance mechanisms in Pseudomonas aeruginosa are more frequently regulated by alterations in membrane permeability through porin channels and efflux pump expression.…

  • Liver Cancer Breakthrough Unveiled at ESMO 2024!

    Thrilled to share our interview with Professor Guohong Han about the LEAP-012 study, which could revolutionize liver cancer treatment! Combining TACE with lenvatinib and pembrolizumab is showing incredible results for intermediate-stage liver cancer: 46.8% tumor response rate Progression-free survival boosted from 10 to 14.6 months